Consumer medical devices (CMD) are sold over-the-counter (OTC) at non-specialty retail locations including drug stores, grocery stores, convenience stores, and online. They have established safety profiles and are for use by consumers in non-clinical environments. Generally, no training is necessary to use a CMD. Manufacturers of CMDs rely on labeling, design, and consumer familiarity to ensure safe and effective use. Most CMDs are not subject to FDA’s premarket review requirements.
Statement on Biden Executive Order Regarding OTC Hearing Aids from Peter Borsuk, Chair of CHPA’s Consumer Medical Devices Council, and President & CEO of Lansinoh Laboratories.
Prior to the pandemic, the self-care sector was already expanding rapidly, with health spending increasing 31-fold per capita over the past four decades. IRI and CHPA recently released this report about how consumer self-care has specifically changed.
Consumer self-care changed during the COVID-19 pandemic. This report from IRI and CHPA divides consumers into seven distinct segments and discussed how CPGs and retailers can reach them with the right health and wellness solutions.
CHPA launched a new podcast – CHPA Chat – providing stories and insights from staff, industry leaders, academics, and healthcare providers about the trends and issues facing the consumer healthcare space.
For its annual year-in-review series, Chain Drug Review featured CHPA's President & CEO, Scott Melville, who offered industry insights from last year and thoughts on the outlook for 2021.